>>PAR2 (1-6) amide (human) (scrambled) (trifluoroacetate salt)

PAR2 (1-6) amide (human) (scrambled) (trifluoroacetate salt) (Synonyms: LSIGKV-NH2)

Catalog No.GC45540

 

Products are for research use only. Not for human use. We do not sell to patients.

PAR2 (1-6) amide (human) (scrambled) (trifluoroacetate salt) Chemical Structure

Size 가격 재고 수량
1mg
US$60.00
재고 있음
5mg
US$271.00
재고 있음
10mg
US$479.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com


고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

PAR2 (1-6) amide (human) (scrambled) is a synthetic peptide that corresponds to residues 1-6 of the amino terminal tethered ligand of human PAR2 sequence with the amino acids at positions 1 and 2 reversed. It has been used as a negative control for the proteinase-activated receptor 2 (PAR2) agonist PAR2 (1-6) (human) in various cellular assays.1,2

References
1. Miyata, S., Koshikawa, N., Yasumitsi, H., et al. Trypsin stimulates integrin a5b1-dependent adhesion to fibronectin and proliferation of human gastric carcinoma cells through activation of proteinase-activated receptor-2. J. Biol. Chem. 275(7), 4592-4598 (2000).
2. Miike, S., McWilliam, A.S., and Kita, H. Trypsin induces activation and inflammatory mediator release from human eosinophils through protease-activated receptor-2. J. Immunol. 167(11), 6615-6622 (2001).

리뷰

Review for PAR2 (1-6) amide (human) (scrambled) (trifluoroacetate salt)

Average Rating: 5 ★★★★★ (Based on Reviews and 36 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for PAR2 (1-6) amide (human) (scrambled) (trifluoroacetate salt)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.